<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To demonstrate the presence of <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> in <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (PAPS) patients without accompanying <z:hpo ids='HP_0001409'>portal hypertension</z:hpo> or comorbidity </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Twelve patients (7 women) aged 23-65 years followed upon the diagnosis of PAPS were enrolled in the study </plain></SENT>
<SENT sid="2" pm="."><plain>We documented the identified causes of <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> in patients with PAPS, and searched for the potential causes of <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> in patients with spleen enlargement </plain></SENT>
<SENT sid="3" pm="."><plain>PAPS patients with or without <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> were evaluated in terms of demographic and clinical findings </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:hpo ids='HP_0001744'>Splenomegaly</z:hpo> was present in 6 of the 12 patients </plain></SENT>
<SENT sid="5" pm="."><plain>In these patients, there were no <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e>, <z:hpo ids='HP_0001409'>portal hypertension</z:hpo> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> that might lead to <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The long axis of spleen was found to be in the range of 137-155 mm in patients with <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0001744'>Splenomegaly</z:hpo> was more frequently determined in female PAPS patients </plain></SENT>
<SENT sid="8" pm="."><plain>The <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> group had a longer duration of disease (median 5.5 vs. 0.75 years) and a higher number of thrombotic events (median 3 vs. 1.5) </plain></SENT>
<SENT sid="9" pm="."><plain>The <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> group was especially composed of patients who never received any <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and <z:chebi fb="0" ids="15365">acetylsalicylic acid</z:chebi>, or who used these agents irregularly for very short periods </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: <z:hpo ids='HP_0001744'>Splenomegaly</z:hpo> was observed in association with disease duration, frequency of thrombotic events and irregular antiaggregant or <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> treatment in patients with PAPS, in the absence of comorbidity or <z:hpo ids='HP_0001409'>portal hypertension</z:hpo> </plain></SENT>
</text></document>